

Gunderson Dettmer Advises Underwriters on Arcus Biosciences, Inc. “At-the-Market” Offering

Client News

April 2, 2019

Gunderson Dettmer advised underwriters Cantor Fitzgerald & Co. in a proposed \$75,000,000 “at-the-market” offering of shares of Arcus Biosciences, Inc. Public Offerings/Public Companies partners Jeffrey Vetter and Richard Blake and associate Colin Conklin led the team advising Cantor Fitzgerald.

Arcus, which trades on the New York Stock Exchange under the ticker symbol “RCUS,” is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities.

Related People



Jeffrey R. Vetter
PARTNER

P +1 650 321 2400

Related Services

Public Companies

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act